Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients With Low- and Int-1-Risk Myelodysplastic Syndromes: Outcomes From the Randomized, Double-Blind TELESTO Study-MedSci.cn

Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients With Low- and Int-1-Risk Myelodysplastic Syndromes: Outcomes From the Randomized, Double-Blind TELESTO Study

[Anonymous]

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019; 17 (2): 4

科室
- - 订阅+
  - 更多科室
工具
服务